COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #131 of 259
9/5 Late treatment study
Synolaki et al., medRxiv, doi:10.1101/2020.09.05.20184655 (Preprint)
The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
Source   PDF   Share   Tweet
Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients.
Version 1 of this paper stated: "HCQ, AZ, [and ...] were found to be independently associated with survival when treatment commenced at FACTCLINYCoD scores <3".

Synolaki et al., 9/5/2020, retrospective, Greece, Europe, preprint, 20 authors.
risk of death, 23.6% lower, RR 0.76, p = 0.27, treatment 21 of 98 (21.4%), control 60 of 214 (28.0%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 259 studies    Meta analysis
Please send us corrections, updates, or comments.